NeuroMetrix Stock Impressive Rise On Wednesday, Outperforms Market

(VIANEWS) – The NASDAQ ended the session with NeuroMetrix jumping 14.93% to $4.31 on Wednesday, after three sequential sessions in a row of gains. NASDAQ dropped 0.55% to $15,947.74, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

NeuroMetrix’s last close was $3.69, 75.47% under its 52-week high of $15.04.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-5.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.06%.

Moving Average

NeuroMetrix’s worth is way higher than its 50-day moving average of $3.27 and way under its 200-day moving average of $5.45.

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.7%, now sitting on 5.9M for the twelve trailing months.


NeuroMetrix’s last week, last month’s, and last quarter’s current intraday variation average was 2.86%, 0.82%, and 3.24%.

NeuroMetrix’s highest amplitude of average volatility was 8.07% (last week), 4.79% (last month), and 3.24% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuroMetrix’s stock is considered to be oversold (<=20).

More news about NeuroMetrix (NURO).

Leave a Reply

Your email address will not be published. Required fields are marked *